Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » New Insights Into Signaling Pathway Could Lead to Novel Therapies for Neurological Disorders
Scientific Advances

New Insights Into Signaling Pathway Could Lead to Novel Therapies for Neurological Disorders

By Anna WilliamsDec 19, 2016
Share
Facebook Twitter Email
Geoffrey Swanson, PhD, professor of Pharmacology, was the principal investigator of the study, which showed an unexpected signaling pathway present in group I metabotropic glutamate receptors.

Northwestern Medicine scientists have demonstrated an alternate method of signaling by a class of proteins called group I metabotropic glutamate receptors, which are thought to be promising targets in the treatment of a variety of neurological and psychiatric disorders.

The findings, recently published in Nature Communications, could inform ongoing drug development for a number of pathologies, including schizophrenia, pain, Parkinson’s disease and especially fragile X syndrome, a genetic condition that causes developmental disabilities.

The group I metabotropic glutamate receptors, called mGluR1 and mGluR5, serve as modulators of nerve cell excitability and synaptic transmission, or the communication between neurons. Traditionally, they have been described as signaling through a process called G-protein coupling.

In the current study, however, the scientists demonstrated that not all signaling by group I mGluRs is mediated by G proteins. In fact, in some cases they utilize pathways requiring a different protein called β-arrestin2.

“Given that group I mGluRs seem like promising drug targets, at least in these early days, you want to know more about how they really work. And that’s where our study comes in,” said Geoffrey Swanson, PhD, professor of Pharmacology, the lead author of the paper. “We showed that the classical model is too simple, and demonstrated an unexpected way of signaling, downstream of receptor activation.”

By comparing normal mice with mice that lacked either β-arrestin1 or β-arrestin2, and examining various physiological parameters, they discovered that β-arrestin2 was necessary for some forms of mGluR signaling that change the strength of excitatory synapses in the hippocampus.

Future novel drugs might manipulate either pathway, giving scientists more flexibility in how they might tackle neurological disorders.

“That’s the promise of this study,” Swanson said. “If you understand more about how these receptors signal at a basic level, then it allows people in drug development to think in new and different ways about targeting the activity of those receptors in order to achieve a beneficial effect.”

Swanson hopes future research will help understand whether this mode of signaling is unique to the synapses examined in the study, or whether the findings are to some extent generalizable throughout the central nervous system.

The paper’s first author is Andrew Eng, ’16 PhD. Other Northwestern co-authors include postdoctoral fellow Tristan Hedrick, ’13 PhD, and Daniel Kelver.

The research was supported by National Institute of Neurological Diseases and Stroke (NINDS) grant R21NS088916-01.

Neurology and Neuroscience Pharmacology Research
Share. Facebook Twitter Email

Related Posts

Emerging Therapy for Relapsed Lymphoma

Aug 12, 2022

Scientists Identify Key Mechanism Controlling Skin Regeneration

Aug 11, 2022

Scientists Discover Novel Cellular Mechanisms Behind Transcription Elongation

Aug 10, 2022

Comments are closed.

Latest News

Emerging Therapy for Relapsed Lymphoma

Aug 12, 2022

Scientists Identify Key Mechanism Controlling Skin Regeneration

Aug 11, 2022

Scientists Discover Novel Cellular Mechanisms Behind Transcription Elongation

Aug 10, 2022

First-Year Medical Students Celebrate Founders’ Day 2022

Aug 9, 2022

‘Inside Out’ Signaling Promotes Tumor Growth

Aug 5, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
egn-flickr
Founders' Day 2022_EGN-retouched
220805_SERIO_MANDELL_FEINBERG_White_Coat_1676
220805_SERIO_MANDELL_FEINBERG_White_Coat_1206
220805_SERIO_MANDELL_FEINBERG_White_Coat_1144 (1)
220805_SERIO_MANDELL_FEINBERG_White_Coat_1133
220805_SERIO_MANDELL_FEINBERG_White_Coat_1057
220805_SERIO_MANDELL_FEINBERG_White_Coat_1424
220805_SERIO_MANDELL_FEINBERG_White_Coat_1472
220805_SERIO_MANDELL_FEINBERG_White_Coat_1573
220805_SERIO_MANDELL_FEINBERG_White_Coat_1671
220805_SERIO_MANDELL_FEINBERG_White_Coat_1793

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.